Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

NCT01035879 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes

Interventions

DRUG: MBX-2982
DRUG: MBX-2982
DRUG: MBX-2982
DRUG: Sitagliptin
DRUG: placebo

Sponsor

Gilead Sciences